Today, hepatitis C virus infection affects up to 1.5 million people per year and is responsible
for 29 thousand deaths per year. In the 1970s, the clinical observation of unclear, transfusion …

Background & Aims Despite direct-acting antivirals being highly effective at eradicating
hepatitis C virus infection, their impact on the development of hepatocellular carcinoma …

Abstract Background The World Health Organization (WHO) has developed a global health
strategy to eliminate viral hepatitis. We project the treatment and prevention requirements to …

Direct‐acting antiviral agents (DAAs) are highly effective and well tolerated in patients with
chronic hepatitis C virus infection, including those with compensated cirrhosis. However …

Highlights•DAAs for HCV treatment include protease (NS3/4A) inhibitors, RNA-dependent
polymerase (NS5B) inhibitors and NS5A inhibitors.•The combination of DAA owning to …

These updated guidelines from the Infectious Diseases Community of Practice of the
American Society of Transplantation review the diagnosis, prevention, and management of …

Background Real-world data on the efficacy and safety of sofosbuvir plus velpatasvir
(SOF/VEL) treatment for patients with hepatitis C virus (HCV)-related decompensated …

Background: Chronic hepatitis C virus (HCV) infection can lead to liver cirrhosis and its
complications. Viral eradication is essential to prevent disease progression and reduces …

Abstract Background Direct-acting antivirals (DAAs) are safe and effective for the treatment
of HCV infection. However, data regarding their efficacy in patients with Child–Pugh B …

Background Although studies suggest decreased incident hepatocellular carcinoma (HCC)
after direct‐acting antivirals (DAA), data are conflicting regarding HCC recurrence and …